TR199903087T2 - Atardamar trombozuna karsi tek olarak veya trombositlerin plaka halinde birikmesini önleyen unsur ile birlikte Xa faktörü inhibitörü. - Google Patents

Atardamar trombozuna karsi tek olarak veya trombositlerin plaka halinde birikmesini önleyen unsur ile birlikte Xa faktörü inhibitörü.

Info

Publication number
TR199903087T2
TR199903087T2 TR1999/03087T TR9903087T TR199903087T2 TR 199903087 T2 TR199903087 T2 TR 199903087T2 TR 1999/03087 T TR1999/03087 T TR 1999/03087T TR 9903087 T TR9903087 T TR 9903087T TR 199903087 T2 TR199903087 T2 TR 199903087T2
Authority
TR
Turkey
Prior art keywords
combination
alone
factor
agent
platelet aggregation
Prior art date
Application number
TR1999/03087T
Other languages
English (en)
Inventor
Bernat Andre
Marc Herbert Jean
Petitou Maurice
Van Amsterdam Ronald
Original Assignee
Sanofi-Synthelabo
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo, Akzo Nobel N.V. filed Critical Sanofi-Synthelabo
Publication of TR199903087T2 publication Critical patent/TR199903087T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bulus X faktörünün direkt veya indirekt seçmeli engelleyicilerin-faktörünün, yalniz veya antiagregante plaquettaire (levha toplayici karsiti) etkisi olan bir veya daha fazla bilesimlerle birlikte olarak Arteryel Tromboembolik Hastaliklarin önlenmesi veya tedavisi için kullanilmak üzere ilaçlarin hazirlanmasi ve üretilmesi ile ilgilidir. Ayni zamanda Xa Faktörünün bir veya daha fazla indirekt veya antitrombin III vasitasiyla trombositlerin kümelesmesini etkisiz hale getiren bir veya daha fazla bilesik ve muhtemelen farmasötik olarak-eczacilik ve ilaç yapma bakimindan kabul edilir olan bir veya daha fazla eksipiyan vasitalarla birlikte etkili olan direkt seçici inhibitör içeren ilaç bilesimleri bulutu ve bulunmasinin konusunu teskil etmektedir.
TR1999/03087T 1997-06-13 1998-06-09 Atardamar trombozuna karsi tek olarak veya trombositlerin plaka halinde birikmesini önleyen unsur ile birlikte Xa faktörü inhibitörü. TR199903087T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Publications (1)

Publication Number Publication Date
TR199903087T2 true TR199903087T2 (tr) 2000-05-22

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03087T TR199903087T2 (tr) 1997-06-13 1998-06-09 Atardamar trombozuna karsi tek olarak veya trombositlerin plaka halinde birikmesini önleyen unsur ile birlikte Xa faktörü inhibitörü.

Country Status (43)

Country Link
US (2) US6541488B1 (tr)
EP (1) EP0986376B1 (tr)
JP (1) JP3988803B2 (tr)
KR (1) KR100598451B1 (tr)
CN (1) CN1253150C (tr)
AR (1) AR012247A1 (tr)
AT (1) ATE384528T1 (tr)
AU (1) AU728826B2 (tr)
BR (1) BR9810520A (tr)
CA (1) CA2293415C (tr)
CO (1) CO4940476A1 (tr)
CY (1) CY1107912T1 (tr)
CZ (1) CZ299518B6 (tr)
DE (1) DE69839046T2 (tr)
DK (1) DK0986376T3 (tr)
DZ (1) DZ2512A1 (tr)
EE (1) EE04737B1 (tr)
ES (1) ES2299209T3 (tr)
FR (1) FR2764511B1 (tr)
GT (1) GT199800171A (tr)
HK (1) HK1032750A1 (tr)
HR (1) HRP980322B1 (tr)
HU (1) HU227956B1 (tr)
ID (1) ID29309A (tr)
IL (1) IL133452A (tr)
IS (1) IS2619B (tr)
ME (1) ME00685B (tr)
MY (1) MY124648A (tr)
NO (1) NO323739B1 (tr)
NZ (1) NZ501452A (tr)
PL (1) PL193405B1 (tr)
PT (1) PT986376E (tr)
RS (1) RS49902B (tr)
RU (1) RU2212886C2 (tr)
SA (1) SA98190552B1 (tr)
SI (1) SI0986376T1 (tr)
SK (1) SK286311B6 (tr)
TR (1) TR199903087T2 (tr)
TW (1) TW565442B (tr)
UA (1) UA70919C2 (tr)
UY (1) UY25044A1 (tr)
WO (1) WO1998056365A1 (tr)
ZA (1) ZA985137B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
EP1370570B1 (en) * 2001-02-28 2007-01-24 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
US20040067995A1 (en) 2002-10-02 2004-04-08 Wong Pancras C. Novel combination of a factor Xa inhibitor and clopidogrel
WO2004048363A1 (ja) * 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical COMBINED MEDICINES
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
CN101820537B (zh) * 2004-04-23 2013-04-03 住友电气工业株式会社 活动图像数据的编码方法、终端装置以及双向对话型系统
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
EP1991272A2 (en) * 2005-10-10 2008-11-19 N.V. Organon Antithrombotic compound
US20110150976A1 (en) * 2008-09-10 2011-06-23 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
JP6389009B2 (ja) * 2014-10-30 2018-09-12 チェンデュ バイユ ファーマシューティカル カンパニー リミテッドＣｈｅｎｇｄｕ Ｂａｉｙｕ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． ギンコライドＢと第Ｘａ因子阻害剤とを含有する薬物組成物及びその製造方法と用途
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
IL129877A (en) 1996-11-27 2004-08-31 Aventis Pharm Prod Inc A pharmaceutical preparation containing a component having an Xa antagonist activity and an antifouling agent
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
CN1274281A (zh) 2000-11-22
EP0986376B1 (fr) 2008-01-23
NO996137D0 (no) 1999-12-10
IL133452A (en) 2004-09-27
ATE384528T1 (de) 2008-02-15
ME00685B (me) 2008-08-07
PL193405B1 (pl) 2007-02-28
CO4940476A1 (es) 2000-07-24
EE9900574A (et) 2000-08-15
US20040092477A1 (en) 2004-05-13
MY124648A (en) 2006-06-30
EE04737B1 (et) 2006-12-15
BR9810520A (pt) 2000-09-19
GT199800171A (es) 2000-04-21
AR012247A1 (es) 2000-09-27
CZ446099A3 (cs) 2000-04-12
IL133452A0 (en) 2001-04-30
HRP980322A2 (en) 1999-04-30
ZA985137B (en) 1999-01-07
SK286311B6 (en) 2008-07-07
IS5280A (is) 1999-11-30
NZ501452A (en) 2002-06-28
FR2764511A1 (fr) 1998-12-18
HUP0002175A1 (hu) 2000-11-28
RU2212886C2 (ru) 2003-09-27
FR2764511B1 (fr) 2000-09-08
YU63699A (sh) 2002-06-19
JP3988803B2 (ja) 2007-10-10
IS2619B (is) 2010-05-15
JP2002504110A (ja) 2002-02-05
UA70919C2 (uk) 2004-11-15
NO323739B1 (no) 2007-07-02
AU728826B2 (en) 2001-01-18
DE69839046T2 (de) 2009-01-15
TW565442B (en) 2003-12-11
PL337288A1 (en) 2000-08-14
SK170999A3 (en) 2000-07-11
CA2293415A1 (en) 1998-12-17
NO996137L (no) 2000-02-14
SI0986376T1 (sl) 2008-06-30
ID29309A (id) 2001-08-16
DZ2512A1 (fr) 2003-02-01
HU227956B1 (en) 2012-07-30
SA98190552B1 (ar) 2006-09-09
DK0986376T3 (da) 2008-05-13
HUP0002175A3 (en) 2003-05-28
CN1253150C (zh) 2006-04-26
RS49902B (sr) 2008-08-07
PT986376E (pt) 2008-04-01
HK1032750A1 (en) 2001-08-03
CA2293415C (en) 2011-08-09
KR100598451B1 (ko) 2006-07-10
CY1107912T1 (el) 2013-09-04
ES2299209T3 (es) 2008-05-16
AU7924698A (en) 1998-12-30
CZ299518B6 (cs) 2008-08-20
UY25044A1 (es) 2000-10-31
KR20010013690A (ko) 2001-02-26
HRP980322B1 (en) 2003-12-31
WO1998056365A1 (fr) 1998-12-17
DE69839046D1 (de) 2008-03-13
US6541488B1 (en) 2003-04-01
EP0986376A1 (fr) 2000-03-22

Similar Documents

Publication Publication Date Title
TR199903087T2 (tr) Atardamar trombozuna karsi tek olarak veya trombositlerin plaka halinde birikmesini önleyen unsur ile birlikte Xa faktörü inhibitörü.
NZ510509A (en) Compounds that specifically inhibit factor VIIa activity used to inhibit blood clotting and inflammatory response
NO305596B1 (no) 1-(2-okso-acetyl)-piperidin-2-karboksylsyrederivater som multi-medikamentresistente sensitivisatorer for kreftceller
BR9814340A (pt) Derivados de indol como inibidores de fator xa
TR199800019T1 (tr) Trombosit topaklanmasini önleyici yeni maddeler.
DK1068870T3 (da) Antitumormidler
SI0670310T1 (en) Bisulfite adducts of arginine aldehydes useful as thrombin inhibitors and as anticoagulants
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
PT1082321E (pt) Derivados heterociclicos que inibem o factor xa
CA2060507A1 (en) Factor xa based anticoagulant compositions
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
ES2126211T3 (es) Agentes antitromboticos.
DE69713300D1 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
HUP9801593A2 (hu) Benazeprilt vagy benazeprilátot és valzartánt tartalmazó kombinált gyógyszerkészítmények és azok alkalmazása
AU3620799A (en) Heterocyclic derivatives which inhibit factor xa
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
TR200002740T2 (tr) Piperidinil ve N-Amidinopiperidinil türevleri
NO20012944L (no) Fosfolipidkomplekser av proantocyanidin A2 som anti- aterosklerotiske midler
DE60035133D1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
BR9916733A (pt) Derivados de arilalcanoìla, processos para sua preparação, seu uso e composições farmacêuticas que os contêm
TR200201654T2 (tr) Benzamidin türevleri.
TR200101425T2 (tr) IL-5 inhibe edici 6-azaurasil türevleri
RU94022757A (ru) Агент торможения агрегации тромбоцитов
Miller III et al. Relationship between amine-carboxyboranes and TNFα for the regulation of cell growth in different tumor cell lines